Tina's Wish Raises $1.6M for Ovarian Cancer Research and Celebrates its 10th Anniversary at the American Museum of Natural History
National Nonprofit Focused on Ovarian Cancer Research and Early Detection Holds its Annual Benefit Dinner and Celebrates its 10th Year of Raising Funds
NEW YORK, Sept. 29, 2017 /PRNewswire/ -- More than 700 Tina's Wish supporters came together during Ovarian Cancer Awareness Month to raise $1.6M for critical research initiatives at the Foundation's Annual Benefit Dinner on Tuesday, September 26th at the American Museum of Natural History.
This year's dinner honored Susheel Kirpalani, Partner and Chairperson of the Bankruptcy and Restructuring Group at Quinn Emanuel Urquhart & Sullivan, LLP.
"It has been extremely special to see Tina's Wish become a common cause for so many bankruptcy professionals in a relatively short amount of time," said Mr. Kirpalani. "It really speaks volumes about what our community can do when it comes together. As Tina's Wish now commemorates its tenth year, it is the perfect time to look ahead and consider what is possible if we continue to devote more resources to finding an early detection for ovarian cancer. I firmly believe committing to collaboration and innovation will take us a long way in this battle against a truly insidious disease."
Tina's Wish honors the memory of Tina Brozman, former chief judge of the U.S. Bankruptcy Court for the Southern District of New York, who passed away from ovarian cancer in 2007. Since its inception, Tina's Wish has raised over $9 million for its cause. Annually, Tina's Wish now funds $1.2 million of scientific research for the early detection and prevention of ovarian cancer.
Earlier this month, the Foundation announced that it awarded its second Consortium Grant to a team of four researchers from different institutions who will collaborate on the same project for three years. This team includes researchers from Penn Medicine, Memorial Sloan Kettering, Johns Hopkins Medicine and the Wistar Institute.
The majority of ovarian cancer patients are identified in advanced stages due to subtle symptoms and the lack of an effective early detection screening. Statistically, 27% of patients diagnosed during Stage III/IV will survive for only five years, compared to 92% of women diagnosed during Stage I, demonstrating that tools for early detection are critical to changing the global impact of the disease.
To see photos from the event, visit tinaswish.org/benefit17recap.
Contact: Beverly Wolfer
Executive Director
Tina's Wish
212.880.5757
[email protected]
SOURCE Tina's Wish
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article